Dong Bang Co Ltd Strengthens Global Competitiveness with Advanced Veterinary Pharmaceuticals

Dong Bang Co Ltd Strengthens Global Competitiveness with Advanced Veterinary Pharmaceuticals

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dong Bang Co Ltd is strengthening its position in the global veterinary pharmaceutical market with high-value products including pet anesthetics and livestock reproductive hormones. Since its...

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI In treatment-naive patients with advanced NSCLC...

Makuake Hit Product UWANT Flagship V800 Vacuum Officially Launches on Amazon Japan

Makuake Hit Product UWANT Flagship V800 Vacuum Officially Launches on Amazon Japan

TOKYO, May 22, 2026 /PRNewswire/ -- UWANT, a professional brand focused on cleaning appliances, has officially launched its flagship anti-hair tangle self-emptying vacuum cleaner "UWANT V800" on Amazon Japan following its breakout success on...

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be...

ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies

ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies

TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research collaboration with SeromYx Systems, specializing...

Copyright Enforcement Dialogue 2026 in Taipei Reinforces Regional Public-Private Cooperation Against Digital Piracy

Copyright Enforcement Dialogue 2026 in Taipei Reinforces Regional Public-Private Cooperation Against Digital Piracy

TAIPEI, April 23, 2026 /PRNewswire/ -- On April 22, 2026, the Motion Picture Association (MPA) Asia Pacific concluded the Copyright Enforcement Dialogue: Taipei 2026, convening senior policymakers, law enforcement authorities, judicial...

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth

SHANGHAI, April 22, 2026 /PRNewswire/ -- Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to shareholders...

Xinhua Silk Road: Traceability & anti-counterfeiting help ensure reliable quality of green tea in Rizhao

Xinhua Silk Road: Traceability & anti-counterfeiting help ensure reliable quality of green tea in Rizhao

BEIJING, April 14, 2026 /PRNewswire/ -- In Rizhao, one of the world's three major coastal green tea cities, a complete tea industry chain traceability and anti-counterfeiting system is helping the eastern China locality ensure superb quality of...

VEVOR and Rebuilding Together Houston Restore a Legacy Home, One Solution at a Time

VEVOR and Rebuilding Together Houston Restore a Legacy Home, One Solution at a Time

HOUSTON, April 3, 2026 /PRNewswire/ -- For Regina Walker, a breast cancer survivor in Houston's South Union community, her 75-year-old legacy home represents three generations of family memories. However, time and financial hardship had taken a...

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

Earendil Labs Announces First Patient Dosed in a Phase IIa Trial of a Half-life Extended Anti-TL1A Antibody (HXN-1001) in Patients with Ulcerative Colitis

WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa clinical trial of HXN-1001, a half-life extended...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • menu
    menu